Etibo 250 mg

Etibo 250 mg Specification

Dosage Form
Tablet

Packaging Type
Box

Brand Name
Etibo

Life Span
Refer to packaging for expiry

Origin of Medicine
India

Salt Composition
Lapatinib

Pacakaging (Quantity Per Box)
30 Tablets

Indication
Treatment of breast cancer

Drug Type
Prescription Medicine

Ingredients
Lapatinib Tablets IP

Physical Form
Tablet

Function
Anticancer (Tyrosine kinase inhibitor)

Recommended For
For Oral Use

Dosage
250 mg

Dosage Guidelines
As prescribed by physician

Suitable For
Adults

Quantity
1 x 30 Tablets

Storage Instructions
Store in a cool and dry place

Shape
Not specified on the box

Color
Not specified on the box

Prescription Required
Yes

Route of Administration
Oral

Strength
250 mg

About Etibo 250 mg

Etibo 250 mg presents a pivotal advancement in oral cancer therapy. Commanding attention for its crowning achievements in oncological care, this cost-effective, prescription-only medication contains the active ingredient Lapatinib. Designed for adults, Etibo's ephemeral intervention targets breast cancer through tyrosine kinase inhibition. Each box offers 30 tablets, perfectly tailored to be taken under a physician or oncologist's guidance. With clearance from respected authorities and a clinical reputation, Etibo 250 mg offers a dependable option to empower patients through their crucial treatment journey.

Effective Application and Recommended Use

Etibo 250 mg tablets are intended specifically for oral administration, demonstrating high applicability on the internal biological surface via ingestion. The application media is strictly oral, ensuring straightforward use for eligible adults. Directions of use mandate strict adherence to the onco-specialist's prescription, optimizing therapeutic outcomes for breast cancer treatment. The tablets should be swallowed whole with water, never chewed or crushed, to maintain efficacy. Dosing schedules are determined individually by the treating physician for maximum benefit.

Certifications and Export Parameters

Etibo 250 mg is supplied and handed over only under prescription, maintaining compliance with stringent pharmacological standards in India. Upon arrival in export markets, Etibo meets the expectations of healthcare authorities, though packaging contains no explicit product registration number. Our sample policy offers potential buyers an exploration of product quality. Main export markets include regions seeking affordable, effective anticancer therapies, and clients are encouraged to reach out for detailed certification and sample inquiry processes.

FAQ's of Etibo 250 mg:

Q: How should Etibo 250 mg be administered for the best results?

A: Etibo 250 mg tablets must be taken orally, as directed by your oncologist. Do not chew or crush the tablets; swallow them whole with water for optimal absorption and efficacy.

Q: What is the primary benefit of using Etibo 250 mg in breast cancer treatment?

A: Etibo 250 mg, containing Lapatinib, acts as a tyrosine kinase inhibitor. It targets cancer cells and helps slow or stop their growth, providing a pivotal advantage in the management of certain breast cancers.

Q: When should I start taking Etibo 250 mg during my treatment process?

A: Start Etibo 250 mg only after receiving a prescription from your oncologist. Your treatment commencement time and dosage schedule are determined based on your unique clinical scenario.

Q: Where should Etibo 250 mg be stored to maintain its effectiveness?

A: To ensure maximum efficacy, store Etibo 250 mg tablets in a cool and dry place, away from moisture and direct sunlight, as specified in the storage instructions.

Q: What process is involved in obtaining Etibo 250 mg for treatment?

A: To obtain Etibo 250 mg, you need a prescription from a qualified physician. Once prescribed, you can purchase the medicine from a licensed pharmacy or authorized supplier.